|Bid||1.9100 x 4000|
|Ask||1.9600 x 3000|
|Day's Range||1.8950 - 1.9850|
|52 Week Range||1.2300 - 3.1000|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.17|
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to R835, the company's investigational IRAK1/4 inhibitor, will be presented in two oral and two poster presentations at the European League Against Rheumatism (EULAR) 2020 E-Congress taking place June 3-6, 2020. A fifth abstract highlighting R835 has been accepted for publication. The presentations will be made available on the event's website at https://congress.eular.org/ on Wednesday, June 3 at 1:00 AM CEST.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:30 p.m. Eastern Time.
Investors in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) had a good week, as its shares rose 7.0% to close at US$1.83...
It is now my pleasure to introduce our first speaker, Dolly Vance, who is Rigel's Executive Vice President of Corporate Affairs and General Counsel. As a reminder, during today's call we may make forward-looking statements regarding our financial outlook and our plans and timings for regulatory and product development. At this time, I would like to turn the call over to our CEO, Raul Rodriguez.
Rigel (RIGL) delivered earnings and revenue surprises of 0.00% and -2.08%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2020, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that, due to public health and safety concerns related to the coronavirus ("COVID-19") pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others, it will host its 2020 Annual Meeting of Stockholders ("Annual Meeting") as a virtual-only meeting that will be held via live audio webcast. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting.
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2020 financial results after market close on Tuesday, May 5, 2020. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders should be happy to see the share price up 23% in the last week...
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2019 financial results after market close on Thursday, February 27, 2020. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results.
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update, including preliminary product revenue and total TAVALISSE® (fostamatinib disodium hexahydrate) bottles for the quarter; the European Commision's (EC) approval of fostamatinib disodium hexahydrate (fostamatinib) for adult patients with chronic immune thrombocytopenia (ITP); and enrollment progress in its Phase 3 pivotal trial for warm autoimmune hemolytic anemia (AIHA). The company's president and CEO, Raul Rodriguez, will provide a more detailed company overview during his presentation taking place on Thursday, January 16 at 7:30am PT at the 38th Annual J.P. Morgan Healthcare Conference.
Raul Rodriguez became the CEO of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) in 2014. This report will, first, examine...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, is scheduled to present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 7:30am PT in San Francisco, CA.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 17) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that Eldon Mayer has resigned from his position as chief commercial officer effective December 23, 2019, to pursue an opportunity with an emerging company.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]